- Quizartinib (AC220)
- Cabozantinib (XL184, BMS-907351)
- TG101209
- Amuvatinib (MP-470, HPK 56)
- G-749
AST 487RET kinase inhibitor |
Sample solution is provided at 25 µL, 10mM.
Quality Control & MSDS
- View current batch:
- Purity = 98.00%
- COA (Certificate Of Analysis)
- MSDS (Material Safety Data Sheet)
- Datasheet
Chemical structure
Related Biological Data
Description | AST487 is an inhibitor of RET kinase with IC50 value of 0.88 μM. | |||||
Targets | RET kinase | |||||
IC50 | 0.88 μM |
Cell experiment [1]: | |
Cell lines | Baf3 cells |
Preparation method | The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months. |
Reaction Conditions | 10 min; IC50=34±4 nmol/L |
Applications | Data derived from a panel of Baf3 murine pro–B cell lymphoma lines rendered growth factor–independent by transduction with various activated tyrosine kinases, suggested cellular specificity for RET-driven proliferation (IC50 for PTC3-RET–driven Baf3 cells, 34±4 nmol/L), with activity against FLT3 as well, and to a lesser extent,Bcr-ABL–dependent proliferation |
Animal experiment [1]: | |
Animal models | Female athymic nude mice |
Dosage form | 50 mg/kg; oral taken |
Applications | NVP-AST487 given p.o. evoked a dose-dependent inhibition of growth of NIH3T3-RETC634W xenografts, with doses >30 mg/kg/d causing significant reductions in tumor size. The effects of the compound on RET expression and phosphorylation in tumor extracts was analyzed 6 h following the final treatment. Reductions in tumor RET phosphorylation in NVP-AST487–treated animals were clearly seen, particularly at doses ≥30 mg/kg. Interestingly, there was also a dose-dependent decrease of RET expression, with one of three tumors analyzed in the 30 mg/kg group and three of three tumors in the 50 mg/kg group showing a dramatic reduction in RET protein levels. |
Other notes | Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
References: [1] Yu K, Toral-Barza L, Shi C, et al. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin[J]. Cancer research, 2009, 69(15): 6232-6240. |
AST 487 Dilution Calculator
calculate
AST 487 Molarity Calculator
calculate
Cas No. | 630124-46-8 | SDF | Download SDF |
Synonyms | NVP-AST 487 | ||
Chemical Name | 1-[4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[4-[6-(methylamino)pyrimidin-4-yl]oxyphenyl]urea | ||
Canonical SMILES | CCN1CCN(CC1)CC2=C(C=C(C=C2)NC(=O)NC3=CC=C(C=C3)OC4=NC=NC(=C4)NC)C(F)(F)F | ||
Formula | C26H30F3N7O2 | M.Wt | 529.56 |
Solubility | ≥26.5 mg/mL in DMSO, ≥51.2 mg/mL in EtOH, <2.54 mg/ml="" in="" h2o="">2.54> | Storage | Store at -20°C |
Shipping Condition | Evaluation sample solution : ship with blue ice.All other available size:ship with RT , or blue ice upon request | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. |
AST487 is an inhibitor of RET kinase with IC50 value of 0.88μM [1].
AST487 belongs to the N,N’-diphenyl urea class. It inhibit the activity of RET kinase as well as many other kinases( such as KDR, Flt-3 and c-Kit) in vitro. In the cell assay, the inhibition effect of AST487 is displayed both in PC-RET/PTC3 cells and TT cells, which harbor an endogenous activating point mutation of RET (RETC634W). AST487 decreases RET autophosphorylation and activation of PLCγ and ERK with a dose-dependent manner. Additionally, AST487 is also found to inhibit the growth of human thyroid cancer cell lines with RET, but not BRAF mutations. It supports the selectivity of AST487 for RET. In vivo assay shows that AST487 causes significant reductions in the size of NIH3T3-RETC634W xenografts with doses >30 mg/kg/d and oral administration of AST487 at 50 or 30 mg/kg/d decreases mean tumor volume in mice [1].
References:[1] Nagako Akeno-Stuart, Michelle Croyle, Jeffrey A. Knauf, et al. The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells. Cancer Res. 2007, 67:6956-6964.
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
质粒转染一般是说DNA转染,用常用的sinofection等转染试剂就可以;
小干扰RNA(Small interfering RNA;siRNA)有时称为短干扰RNA(short interfering RNA)或沉默RNA(silencing RNA),是一个长20到25个核苷酸的双股RNA,这种RNA的转染需要用专门的RNA转染试剂。
如题,PolyplusTransfection转染试剂在中国区的代理商有哪些?求推荐1-2个靠谱的,谢谢!
想用RNAiMAX或者lipo2000转染siRNA,但是看了下转染试剂的说明书和锐博的siRNA说明书,觉得分别对siRNA的用量描述差别挺大的呀,不知道到底该参考哪个呢。
以24孔板为例在siRNA说明书中写到,siRNA终浓度是50nM的话,加入浓度为20μM的siRNA1.25ul,每孔体积是500ul,那这样的话,每孔最终siRNA的量是25pmol。
但是在RNAiMAX或者是lipo2000说明书中,一个写的每孔siRNA用量是5pmol,一个是500ng,这与siRNA厂家所提供的量相差也太多了吧。
到底该看哪一个呢。
ps.一旦siRNA的量和体积确定下来之后,转染试剂的量和siRNA1:1的加就可以了吗?
请各位大神解答。
1.siRNA说明书中的用量,红线圈出
2.RNAIMAX说明书中siRNA的用量。
3.lipo2000说明书中siRNA用量
对重复性要求不高的试验,一般没有问题的,只不过可能需要增加一些转染试剂用量了。
为了避免这个问题,推荐收到货之后,进行适当分装,用多少,拿出来多少最好。
但是在选择的时候,也需要注意其他的一些问题。
1、采用何种原料和抗体,是否高效、灵敏、特异
2、规范包被操作,吸附是否均匀
3、重复性、可靠性
6、是否提供技术服务
7、适用于血浆、血清、组织匀浆液、细胞培养上清液、尿液等多种类型的样本
8、可检测动物类型是否丰富
9、可检测指标是否齐全
elisa试剂盒就查下博欧特生物
使用方法:
1、 血清:操作过程中避免任何细胞刺激。使用不含热原和内毒素的试管。收集血液后,1000×g离心10分钟将血红细胞迅速小心地分离。
2、 血浆:EDTA、柠檬酸盐、肝素血浆可用于检测。1000×g离心30分钟去除颗粒。
3、 细胞上清液:1000×g离心10分钟去除颗粒和聚合物。
4、 组织匀浆:将组织加入适量生理盐水捣碎。1000×g离心10分钟,取上清液。
5、 保存:如果样品不立即使用,应将其分成小部分-70℃保存,避免反复冷冻。尽可能的不要使用溶血或高血脂血。如果血清中大量颗粒,检测前先离心或过滤。不要在37℃或更高的温度加热解冻。应在室温下解冻并确保样品均匀地充分解冻。
内毒素是革兰氏阴性菌细胞壁(cellwall)上的特有成分,主要是脂多糖中的类脂A,在细菌被裂解时被释放出来,由于其化学结构和特性,在质粒的纯化过程中很容易混入质粒DNA一同提取出来。内毒素的存在会严重的影响质粒转染细胞的效率,此外会激活造血细胞(如B细胞、巨噬细胞等)的非特异免疫反应,造成实验的假阳性,所以转染级质粒的提取纯化必须去除内毒素。